机译:基于白蛋白 - 胆红素级级的综合模型作为索拉非尼肝癌失败的预测因子的综合模型
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Department of NursingTaipei Veterans General HospitalTaipei Taiwan;
Cancer CenterTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Institute of Clinical MedicineNational Yang‐Ming UniversityTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
Division of Gastroenterology and HepatologyTaipei Veterans General HospitalTaipei Taiwan;
advanced hepatocellular carcinoma; ALBI ‐ PD criteria; new extrahepatic metastasis; post‐sorafenib second‐line treatment;
机译:基于白蛋白 - 胆红素级级的综合模型作为索拉非尼肝癌失败的预测因子的综合模型
机译:白蛋白 - 胆红素和血小板 - 白蛋白 - 胆红素等级精确地预测高危患者的整体存活,以常规的常规常规化疗栓塞治疗肝细胞癌
机译:白蛋白 - 胆红素级对接受Sorafenib的肝细胞癌患者存活的影响:使用时间依赖接收机的分析
机译:Sorafenib之外的肝细胞癌中的分子疗法:III期试验失败的课程和新型靶标
机译:基线多伦多HCC风险指数(THRI)和白蛋白预测HCV感染持续病毒响应(SVR)后肝细胞癌(HCC)的低风险
机译:白蛋白 - 胆红素指数和血小板 - 白蛋白 - 胆红素指数有助于鉴定肝细胞癌和儿童-PUGH级患者的存活益处候选者与Sorafenib治疗
机译:基线白蛋白 - 胆红素等级对越南肝细胞癌肝癌患者预测总生存的作用